Scarica l'app Stockscreener
38.87
4.05%
-1.64
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$40.51
Aprire:
$40.375
Volume 24 ore:
2.05M
Relative Volume:
0.86
Capitalizzazione di mercato:
$6.64B
Reddito:
-
Utile/perdita netta:
$-354.30M
Rapporto P/E:
-15.40
EPS:
-2.5234
Flusso di cassa netto:
$-286.27M
1 W Prestazione:
+0.47%
1M Prestazione:
+23.87%
6M Prestazione:
+9.96%
1 anno Prestazione:
+258.25%
Intervallo 1D:
$38.31
$40.54
Intervallo di 1 settimana:
$38.10
$40.89
Portata 52W:
$10.38
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Nome
Cogent Biosciences Inc
Settore
Industria
Telefono
617-945-5576
Indirizzo
275 WYMAN STREET, WALTHAM
Compare COGT vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
38.87 | 6.64B | 0 | -354.30M | -286.27M | -2.5234 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-16 | Ripresa | Jefferies | Buy |
| 2025-11-10 | Aggiornamento | Stifel | Hold → Buy |
| 2025-11-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-10-16 | Iniziato | Stifel | Hold |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-11 | Downgrade | Needham | Buy → Hold |
| 2024-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Iniziato | Citigroup | Buy |
| 2023-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-12-08 | Iniziato | JP Morgan | Overweight |
| 2023-04-28 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-27 | Ripresa | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-06-28 | Iniziato | Guggenheim | Buy |
| 2021-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-09 | Ripresa | Jefferies | Buy |
| 2020-12-23 | Iniziato | Piper Sandler | Overweight |
| 2020-10-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
Price to sales forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
(COGT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Enterprise value to EBITDA forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
Cogent Biosciences (COGT) Files FDA Application As Bezuclastinib Hype Meets A Pricey Valuation - Sahm
Price to book forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
Is Bezuclastinib’s FDA Filing And Disease-Modifying Data Altering The Investment Case For Cogent Biosciences (COGT)? - simplywall.st
Cogent Biosciences (COGT) director takes options in lieu of cash - Stock Titan
Cogent Biosciences (COGT) Edges Higher, Tests Key Resistance Amid Sector TailwindsFlat Correction - dars.gov.et
Enterprise value to revenue forward of Cogent Biosciences, Inc. – NASDAQ:COGT - TradingView
3 Reasons Cogent Biosciences (COGT) Looks Pricey After Its FDA Filing - Sahm
COGTCogent Biosciences Inc Forecast, Target Price - Finviz
How (COGT) Movements Inform Risk Allocation Models - Stock Traders Daily
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Advanced Systemic Mastocytosis - Investing News Network
Cogent Biosciences Submits US FDA New Drug Application for Potential Mast Cell Disease Treatment - marketscreener.com
Cogent Biosciences (COGT) Submits NDA to FDA for Bezuclastinib - GuruFocus
Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) - The Manila Times
Cogent Biosciences Announces Submission of New Drug - GlobeNewswire
Cogent seeks FDA approval for rare blood disease drug - Stock Titan
Why Cogent Biosciences (COGT) Is Up 6.7% After Russell Index Removal Reshapes Its Investor Base - simplywall.st
Cogent Biosciences stock retreats after recent gains as bullish momentum consolidates - Traders Union
Cogent Biosciences stock edges lower with sideways action after Elevation Summit event - Traders Union
Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell 2000 Value Benchmark - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Cogent Biosciences, Inc. Actuals & Estimates (NASDAQ:COGT) - TradingView
Cogent Biosciences, Inc.(NasdaqGS:COGT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell Microcap Index - marketscreener.com
Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell 3000E Value Benchmark - marketscreener.com
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Ros Matthew - Moomoo
Cogent Biosciences, Inc.(NasdaqGS: COGT) dropped from Russell 3000E Index - marketscreener.com
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Director Shegog Todd - Moomoo
Cogent Biosciences | 4: Statement of changes in beneficial ownership of securities-Officer Robbins Andrew R - Moomoo
COGT Forecast — Price Target — Prediction for 2027 - TradingView
Cogent (COGT) Presents Preclinical Data for Novel JAK2 Inhibitor CGT1145 at 2026 EHA Congress - Insider Monkey
Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market? - Yahoo Finance
New Bezuclastinib and JAK2 Data Could Be A Game Changer For Cogent Biosciences (COGT) - Sahm
Trading Systems Reacting to (COGT) Volatility - Stock Traders Daily
H.C. Wainwright Sticks to Its Buy Rating for Cogent Biosciences (COGT) - The Globe and Mail
H.C. Wainwright Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Cogent Biosciences Inc (COGT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cogent Biosciences Inc (COGT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cogent Biosciences Inc (COGT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cogent Biosciences Inc (COGT) Institutional Confidence - TradingKey
Cogent Biosciences Inc (COGT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cogent Biosciences Inc (COGT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cogent Biosciences Inc (COGT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cogent Biosciences (COGT) Gains 1.92% as Biotech Sector Momentum BuildsLeveraged ETF Flow - Město Břeclav
Cogent Biosciences Inc (COGT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cogent Biosciences Inc (COGT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Stifel reiterates Cogent stock Buy rating after trial data - Investing.com UK
Stifel reiterates Cogent stock Buy rating after trial data By Investing.com - Investing.com India
Cogent Biosciences Inc Azioni (COGT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.64%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):